Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 79.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 111,828 shares of the company’s stock after purchasing an additional 49,527 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.07% of Neumora Therapeutics worth $1,099,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Amalgamated Bank raised its holdings in Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after purchasing an additional 2,402 shares in the last quarter. SkyOak Wealth LLC acquired a new stake in Neumora Therapeutics during the second quarter worth approximately $147,000. Principal Financial Group Inc. acquired a new stake in Neumora Therapeutics during the second quarter worth approximately $166,000. SG Americas Securities LLC acquired a new stake in Neumora Therapeutics during the second quarter worth approximately $566,000. Finally, Nan Fung Group Holdings Ltd acquired a new stake in Neumora Therapeutics during the first quarter worth approximately $871,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA opened at $15.51 on Friday. The firm has a market capitalization of $2.48 billion and a P/E ratio of -6.06. Neumora Therapeutics, Inc. has a one year low of $8.33 and a one year high of $21.00. The company’s fifty day moving average is $12.26 and its two-hundred day moving average is $11.25.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37). On average, sell-side analysts forecast that Neumora Therapeutics, Inc. will post -1.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Neumora Therapeutics

In other Neumora Therapeutics news, insider Robert A. Lenz sold 5,563 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total value of $83,500.63. Following the transaction, the insider now directly owns 322,966 shares in the company, valued at approximately $4,847,719.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Robert A. Lenz sold 30,788 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the completion of the sale, the insider now owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total transaction of $83,500.63. Following the sale, the insider now directly owns 322,966 shares of the company’s stock, valued at approximately $4,847,719.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 96,489 shares of company stock worth $1,151,258. Corporate insiders own 26.40% of the company’s stock.

Wall Street Analyst Weigh In

NMRA has been the topic of a number of recent research reports. Mizuho initiated coverage on shares of Neumora Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $20.00 target price on the stock. HC Wainwright initiated coverage on shares of Neumora Therapeutics in a report on Tuesday, October 1st. They issued a “buy” rating and a $30.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a report on Thursday, September 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $22.83.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.